Description: Trilaciclib hydrochloride (G-1T28; Cosela), the hydrochloride salt of Trilaciclib, is a short-acting CDK4/6 inhibitor with anticancer activity. It inhibits CDK4/6 with IC50s of 1 nM and 4 nM, respectively. Trilaciclib was approved in 2021 by FDA as a myelopreservation therapy to reduce the frequency of chemotherapy-induced bone marrow suppression.

References:

[1]. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93; H

[2]. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med. 2017 Apr 26;9(387).

Related CAS #: 1977495-97-8 (HCl) 1374743-00-6 (free base)

纯度：≥98%

CAS：1977495-97-8